UNSPSC 51351513: Pregnenolone

This classification denotes a therapeutic progestin with the molecular formula C21H32O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 73R90F7MQ8, chemically known as 17.alpha.-pregn-5-en-20-one, 3.beta.-hydroxy- but generally known as pregnenolone, which bears US NIH Compound Identifier 1027. European Medicines Agency schedules Pregnenolone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10024MIG. The term PREGNENOLONE is an International Non-Proprietary Name.

UNSPSC 51351513 Pregnenolone is a Commodity code representing a specific pharmaceutical active ingredient typically procured through multistate cooperative purchasing agreements for distribution across state and local healthcare facilities. State and local governments source pregnenolone primarily as part of broader generic pharmaceutical and over-the-counter product portfolios rather than as standalone line items, with suppliers required to meet FDA compliance, current Good Manufacturing Practices certification, and Drug Supply Chain Security Act requirements. Procurement is heavily weighted toward pricing competitiveness—typically 75 percent of evaluation criteria—with secondary consideration for administrative compliance, electronic data interchange capability, and pricing format flexibility (flat price, net pricing tiers, or WAC-minus structures). Issuing bodies include multistate cooperative purchasing alliances administering agreements on behalf of multiple participating state and local member jurisdictions and healthcare facilities, rather than individual cities, counties, or school districts purchasing independently under this code.

The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, issued the most recent relevant opportunity—a Request for Proposal (S1070000015802) posted January 20, 2026, for generic multi-source pharmaceuticals and OTC products with a response deadline of March 26, 2026. The MMCAP agreement covers participating jurisdictions including Minnesota and Oregon, with awarded vendors required to supply through three authorized wholesalers (AmerisourceBergen Drug Corporation/Cencola, Cardinal Health 110 and 112, and Morris & Dickson Co., LLC) and maintain contractual relationships with at least two of the three. The contract runs two years for new responders with optional extensions, effective July 1, 2026, and vendors must carry $5 million commercial general liability insurance, $2 million network security and privacy liability, and $2 million professional liability. No specific dollar values or budget ranges were disclosed; performance penalties range from $200 to $1,500 per violation for late reporting, missed onboarding, or improper class-of-trade denials.